Tracing a drug's price from manufacturer list (WAC) down through wholesaler, PBM, plan, and pharmacy deductions to realized net price
Every dollar in the US drug supply chain traces back to a single filed number: Wholesale Acquisition Cost. WAC is published by the manufacturer to pricing compendia (Medi-Span, First Databank) and is never actually paid in full by anyone downstream — yet it anchors distribution fees, patient coinsurance, 340B ceiling prices, and Medicaid rebate formulas alike.
Wholesale Acquisition Cost is defined by statute (Medicaid Drug Rebate Program, 42 U.S.C. §1396r-8) as the manufacturer's published list price to wholesalers or direct purchasers, exclusive of prompt-pay or other discounts. Critically, WAC is a benchmark, not a transaction price — essentially no purchaser in the supply chain pays WAC in cash.
WAC nonetheless matters enormously because it is the reference point multiplied, discounted, or capped by nearly every other price in the system:
• AWP (Average Wholesale Price): historically an independently reported "street price," now set almost universally at WAC × 1.20 by compendia convention since major AWP litigation settlements in the mid-2000s (e.g., In re Pharmaceutical Industry Average Wholesale Price Litigation) • NADAC (National Average Drug Acquisition Cost): CMS survey-based benchmark of actual retail pharmacy acquisition cost, used for Medicaid pharmacy reimbursement — typically 15–25% below WAC • ASP (Average Sales Price): manufacturer-reported quarterly net-of-rebate price used for Medicare Part B physician-administered drugs, calculated completely independently of WAC • 340B ceiling price: statutory formula = AMP − Unit Rebate Amount, indirectly bounded by WAC-linked launch pricing
Because coinsurance, deductibles, and many stop-loss/reinsurance contracts are calculated as a percentage of the list-adjacent price at the pharmacy counter, WAC increases translate almost mechanically into higher out-of-pocket costs for patients — even when the manufacturer's net price is falling.
Manufacturers face a structural incentive to raise WAC even as competitive rebating erodes net revenue: because PBM formulary rebates are contracted as a percentage of WAC, a higher list price generates a larger absolute rebate dollar pool to offer PBMs for preferred placement — without changing the manufacturer's realized net price by much, since the rebate percentage scales proportionally.
This dynamic, widely documented by the Drug Channels Institute and SSR Health's gross-to-net (GTN) tracking series, produces the now-familiar divergence: branded drug list prices rose a median of ~4–6% annually through the early 2020s, while net prices (after rebates) were flat or declining in real terms for many chronic-disease classes. Insulin is the canonical case — list prices for analog insulins roughly tripled between 2007 and 2018 while manufacturer net revenue per unit was reported as flat to declining, because rebates to PBMs absorbed nearly all of the list-price growth.
A 2021 House Oversight Committee investigation found that for several top-selling insulin products, the manufacturer net price fell by double digits between 2014 and 2018 even as the WAC list price rose by more than 50% over the same period — the gap was entirely absorbed by rebates paid to PBMs for formulary access.
Before a drug reaches any pharmacy shelf, it passes through one of three dominant wholesalers, which physically distribute more than 90% of US pharmaceutical volume. Manufacturers pay these wholesalers a Distribution Service Agreement (DSA) fee, typically 3–5% of WAC, plus additional prompt-pay discounts — the first, smallest, but most mechanical layer of the rebate waterfall.
Prior to the early 2000s, wholesalers profited from "buy-and-hold" arbitrage — purchasing inventory ahead of announced price increases and reselling at the new, higher price. Manufacturers restructured contracts into Fee-for-Service (FFS) / Distribution Service Agreements specifically to eliminate this speculative margin.
Under modern DSAs:
• The wholesaler is paid an explicit percentage of WAC (commonly 3.0–4.5%) for logistics, warehousing, and inventory-financing services — regardless of any price change • A separate prompt-pay discount (~2%) rewards the wholesaler for remitting payment within the invoice terms (net 30–45 days), common across the industry • Chargebacks reconcile the gap when a wholesaler resells to a customer entitled to a lower contract price (e.g., a 340B hospital or GPO member) than the wholesaler paid the manufacturer — the manufacturer refunds the wholesaler the difference
Because distribution fees are a small, fixed percentage of WAC, this stage of the waterfall is the most predictable and least strategically contested — the real battleground for rebate dollars begins one stage downstream, at the PBM.
Group Purchasing Organizations (GPOs) negotiate contract prices on behalf of member hospitals and health systems, typically well below WAC for hospital-administered drugs. When a wholesaler sells to a GPO member at the negotiated contract price, it invoices the manufacturer for a chargeback equal to the difference between what it paid the manufacturer (near WAC) and what it collected from the buyer (the lower contract price).
Chargeback processing is a substantial administrative operation: large specialty manufacturers process hundreds of thousands of chargeback line items monthly, reconciled through 852/867 EDI transaction data. Chargeback accuracy and timing materially affect a manufacturer's quarterly net-price accounting under ASC 606, since the expected chargeback amount must be accrued as variable consideration at the time of the original wholesaler sale — well before the actual GPO transaction occurs.
Pharmacy Benefit Managers control formulary access for the vast majority of US covered lives, and the three largest — CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth) — administer roughly 80% of prescription claims nationally. In exchange for preferred tier placement, reduced prior authorization, and volume commitments, manufacturers pay PBMs a rebate off WAC that is by far the largest single deduction in the entire waterfall.
A PBM's core commercial lever is the formulary — the tiered list of covered drugs mapped to patient cost-share. Manufacturers bid rebate percentages to secure Tier 2 (preferred brand) rather than Tier 3 (non-preferred) or exclusion entirely, because tier position drives prescription volume through both lower patient copay and reduced administrative friction (prior authorization, step therapy).
Rebate negotiation dynamics scale directly with intra-class competition:
• Multi-source therapeutic classes (statins, insulins, PCSK9 inhibitors, TNF-inhibitor biosimilars): 3+ clinically interchangeable competitors bid aggressively for exclusive or preferred formulary status, driving rebates to 60–80% of WAC • Sole-source / first-in-class specialty drugs: minimal competitive pressure, rebates commonly 5–15%, sometimes limited to administrative fees only • Rebate "walls": an incumbent with a large existing rebate can effectively block a clinically similar entrant from formulary access, since matching or exceeding the incumbent's rebate percentage may be commercially unsustainable for the new entrant at launch
When Amgen's PCSK9 inhibitor Repatha launched in 2015 at a WAC near $14,000/year, PBM-negotiated rebates reportedly reached 60–75% within several years of competitive entry by Praluent — pushing the realized net price down to roughly $3,000–5,000/year even though the published list price barely moved.
A critical constraint on how deep a manufacturer can rebate commercially is the Medicaid Drug Rebate Program's "Best Price" rule: the lowest price offered to any commercial purchaser (net of rebates, discounts, and price concessions) must also be extended, as a rebate, to state Medicaid programs. Statutory Medicaid rebates already require the greater of 23.1% of Average Manufacturer Price (AMP) or (AMP − Best Price) for branded drugs, plus an inflation penalty when WAC growth outpaces CPI-U.
This creates a structural ceiling: manufacturers are wary of offering commercial PBM rebates so deep that they reset the Best Price benchmark, since doing so would force an equivalent — and permanent — discount to every state Medicaid program. Contract structures increasingly use "nominal price" exclusions, bundled value-based arrangements, and 340B/Medicaid carve-outs specifically to manage this Best Price exposure while still competing aggressively for commercial formulary position.
Rebates collected by the PBM do not stay entirely with the PBM. Under most modern contracts, a substantial share — often 90%+ for large self-insured employers — is passed through to the health plan sponsor, which can use it to lower premiums, fund reinsurance, or increasingly apply it directly at the pharmacy counter to reduce what the patient pays.
For decades, PBM rebates were reconciled on a lagged, aggregate basis: the PBM collected rebates quarterly from manufacturers based on total claims volume across its entire book of business, then remitted a contracted share back to each plan sponsor months later as a lump-sum payment — invisible to the individual patient at the pharmacy counter.
This structure created a well-documented "list price problem": a patient with coinsurance (a percentage of the drug's price rather than a flat copay) pays their share based on the undiscounted price at the counter, even though the plan will later recoup a large rebate the patient never sees. A patient facing 30% coinsurance on a $1,000-WAC drug pays $300 at the counter, while the plan may recover $500+ in rebate months later — the patient effectively overpays relative to the drug's true net cost to the system.
Point-of-sale (POS) rebate programs address this directly: the plan applies some or all of the expected rebate as an immediate price reduction at adjudication, lowering the patient's coinsurance basis in real time. CMS finalized rules enabling — and in some Medicaid managed-care and state-regulated commercial contexts, requiring — POS rebate pass-through, and by the mid-2020s a majority of large commercial plans had adopted at least partial POS rebate sharing for high-rebate drug classes.
A parallel and often confusing layer interacts with rebate pass-through: manufacturer copay assistance programs, which cover some or all of a commercially insured patient's out-of-pocket cost directly. Health plans and PBMs have responded with two counter-strategies:
• Copay accumulator programs: manufacturer coupon dollars are applied to the patient's bill but do NOT count toward the plan's deductible or out-of-pocket maximum — once the coupon is exhausted, the patient owes the full remaining deductible as if the coupon never applied • Copay maximizer programs: the plan spreads the total annual value of available manufacturer copay assistance evenly across 12 months, maximizing how much coupon money the plan can capture over the full benefit year rather than letting it be front-loaded and exhausted early
By 2024, accumulator or maximizer programs applied to a majority of large commercial plan lives in the US, according to AIS Health / MMIT benefit-design tracking — meaning a substantial share of manufacturer copay-assistance spending is effectively redirected into plan/PBM economics rather than reducing the patient's true annual liability.
Two distinct mechanisms operate at the pharmacy dispensing level. Direct and Indirect Remuneration (DIR) fees are retrospective, performance-based clawbacks charged to pharmacies by Part D plan sponsors. Separately — and structurally unrelated to the manufacturer's own rebate contracts — the 340B Drug Pricing Program lets qualifying covered entities buy at a statutory discount and, through contract pharmacy arrangements, sometimes retain the spread on the same insured claim.
Historically, Medicare Part D plan sponsors and their PBMs charged network pharmacies "Direct and Indirect Remuneration" fees months after a prescription was dispensed, based on pharmacy performance metrics (generic dispensing rate, adherence measures, network-quality scores) defined unilaterally in the pharmacy network contract. Because these fees were assessed retroactively, they were invisible at the point of sale — the pharmacy's reported price to CMS (and the patient's calculated cost-share) reflected a higher effective reimbursement than the pharmacy ultimately received once DIR clawbacks were applied.
CMS itself documented that retroactive pharmacy DIR fees grew by roughly 107,000% between 2010 and 2020, and — because DIR fees lowered the net cost used to calculate the Part D "donut hole" coverage gap — they perversely inflated the price point at which beneficiaries entered catastrophic coverage. Effective January 1, 2024, CMS finalized a rule requiring all price concessions from pharmacies, including DIR, to be reflected at the point of sale rather than clawed back later — moving this deduction earlier in the waterfall and making beneficiary cost-sharing more predictable.
The 340B Drug Pricing Program (Public Health Service Act §340B, administered by HRSA) requires manufacturers to sell outpatient drugs to qualifying safety-net providers — disproportionate-share hospitals, federally qualified health centers, Ryan White clinics — at or below a statutory ceiling price, calculated as AMP minus the Medicaid Unit Rebate Amount. For many branded drugs this ceiling sits 25–50%+ below WAC.
The program's "contract pharmacy" expansion — allowing covered entities to dispense 340B-purchased drugs through unlimited retail pharmacy partners rather than only an in-house pharmacy — is the single most contested element of the waterfall's final stage. A covered entity buys at the 340B ceiling price but may bill the patient's commercial or Medicare insurance at the full negotiated (non-340B) rate, retaining the spread between the discounted acquisition cost and the insurance reimbursement. HRSA data show 340B covered entity and contract pharmacy sites grew from roughly 8,100 in 2010 to well over 50,000 sites by the mid-2020s, and total 340B purchases exceeded $50 billion annually — prompting several manufacturers to restrict contract-pharmacy discounts, which HRSA and federal courts have partially contested as violations of the statute's "must offer" requirement.
A 2023 Government Accountability Office review found that 340B discounted purchases for outpatient drugs reached approximately $53.7 billion in a single year, while separately noting that manufacturer restrictions on 340B contract-pharmacy arrangements — implemented by more than fifteen manufacturers since 2020 — remain the subject of ongoing federal litigation over whether covered entities retain an unrestricted right to unlimited contract pharmacy locations.
After every distribution fee, formulary rebate, plan pass-through, and pharmacy-level deduction is summed, what remains is the manufacturer's net price — the revenue actually recognized under ASC 606 variable-consideration accounting. The chasm between that number and the publicly quoted list price is now the defining feature of US drug pricing, with regulatory reform increasingly targeting the gap itself.
Since 2018, US pharmaceutical manufacturers recognize revenue under ASC 606 (Revenue from Contracts with Customers), which requires estimating all variable consideration — rebates, chargebacks, prompt-pay discounts, returns, copay assistance — at the time of the initial sale to the wholesaler, not when each downstream deduction is actually settled. This means a manufacturer must forecast, quarter by quarter, the full gross-to-net bridge for every product based on expected payer mix, formulary status, and historical rebate trend — and true up the accrual as actual claims data arrives.
Gross-to-net (GTN) accrual is one of the most consequential and error-prone estimates in pharma financial reporting: an underestimated rebate accrual inflates reported revenue and requires a later negative revenue restatement, which has triggered SEC scrutiny and earnings restatements at several manufacturers historically. Specialist data providers — SSR Health, IQVIA, DRG/Clarivate — now publish product-level net-price estimates derived from SEC filings, giving investors and policymakers visibility into a number the raw WAC list price obscures entirely.
Because so much of the waterfall's complexity stems from rebating off an inflated list price, several major policy interventions now target net price directly rather than regulating WAC:
• Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program: CMS negotiates a "Maximum Fair Price" directly with manufacturers for selected high-spend Part D and Part B drugs — for the first ten drugs subject to negotiation, negotiated prices announced in 2023 represented discounts of 38–79% off list price, effective 2026, explicitly designed to approximate a defensible net price rather than relying on the existing rebate chain • Most Favored Nation (MFN) proposals: would peg US net price to the lowest price paid in comparable OECD countries, bypassing the domestic rebate waterfall entirely • State list-price transparency laws (e.g., California SB17, several dozen states with WAC-increase reporting mandates) require advance notice and justification of list-price increases above inflation thresholds • ICER (Institute for Clinical and Economic Review) value-based price benchmarks increasingly reference estimated net price, not WAC, when assessing cost-effectiveness — pressuring payers to negotiate toward those benchmarks directly
The long-run trajectory across nearly all of these reforms is the same: shrinking the distance between the list price a patient's coinsurance is calculated against and the net price the manufacturer and payer actually settle on.
CMS estimated that its first round of IRA-negotiated Maximum Fair Prices, covering ten drugs including Eliquis, Jardiance, and Januvia, would have saved the Medicare program approximately $6 billion in net spending for 2023 alone had the negotiated prices been in effect that year — a figure explicitly calculated against net, rebate-adjusted spending rather than list price.